SCHEMBL5364069

SCHEMBL5364069

COc1c(Cl)cc(C=C2C(=O)Nc3ccc(S(=O)(=O)Nc4ccc(C(F)(F)F)cc4)cc32)cc1C(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 4/20 0.54
MOGAT2 Q3SYC2 4/20 0.49
EGFR P00533 2/20 0.48
MGAT2 Q10469 2/20 0.47
LRRK2 Q5S007 1/20 0.45
MEN1 O00255 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
GSK3B P49841 2/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
BRD4 O60885 1/20 0.40
PLK4 O00444 1/20 0.40
PLK1 P53350 1/20 0.40
SYK P43405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367172 0.94 ERBB2 (0.54) ERBB2MOGAT2EGFRMGAT2LRRK2
SCHEMBL5357943 0.91 ERBB2 (0.50) ERBB2MOGAT2EGFRMGAT2LRRK2
SCHEMBL5365889 0.91 ERBB2 (0.63) ERBB2MOGAT2EGFRMGAT2LRRK2
SCHEMBL5377229 0.90 AR (0.47) ERBB2MOGAT2EGFRMGAT2LRRK2
SCHEMBL5363509 0.89 ERBB2 (0.49) ERBB2MOGAT2EGFRMGAT2LRRK2
SCHEMBL5369597 0.86 ERBB2 (0.61) ERBB2MOGAT2EGFRMGAT2MEN1
SCHEMBL5369240 0.86 LRRK2 (0.57) ERBB2MOGAT2MGAT2LRRK2MEN1
SCHEMBL5357751 0.86 MOGAT2 (0.55) ERBB2MOGAT2EGFRMGAT2LRRK2
SCHEMBL5364814 0.86 GSK3B (0.57) ERBB2MOGAT2MGAT2LRRK2MEN1
SCHEMBL5373158 0.86 ERBB2 (0.59) ERBB2EGFRLRRK2GSK3BPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885MOGAT2 1159/4885EGFR 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.